Detalhe da pesquisa
1.
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.
PLoS Pathog
; 19(5): e1011359, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37256916
2.
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.
J Infect Dis
; 226(2): 246-257, 2022 08 24.
Artigo
Inglês
| MEDLINE | ID: mdl-35758878
3.
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.
PLoS Pathog
; 16(6): e1008522, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32589686
4.
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
PLoS Med
; 17(5): e1003117, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32442195
5.
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
PLoS Med
; 17(2): e1003038, 2020 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32092060
6.
Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1.
J Virol
; 93(7)2019 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30700599
7.
Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.
J Virol
; 93(3)2019 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30429340
8.
Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
J Virol
; 93(3)2019 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30429343
9.
HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.
J Virol
; 92(8)2018 04 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29386288
10.
Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates.
J Virol
; 92(8)2018 04 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29437967
11.
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
J Virol
; 91(24)2017 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29021394
12.
Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
J Virol
; 91(19)2017 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28490585
13.
Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
J Virol
; 91(9)2017 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28202751
14.
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
J Virol
; 91(9)2017 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28179536
15.
Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
J Virol
; 90(19): 8644-60, 2016 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27440894
16.
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
J Virol
; 90(8): 4133-4149, 2016 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-26865719
17.
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
J Virol
; 89(16): 8525-39, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-26041302
18.
Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.
J Infect Dis
; 211(4): 508-17, 2015 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25170104
19.
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
N Engl J Med
; 366(14): 1275-86, 2012 Apr 05.
Artigo
Inglês
| MEDLINE | ID: mdl-22475592
20.
Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC".
J Virol
; 93(21)2019 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31615930